Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District [Приобретение ингибиторов ренин-ангиотензин- альдостероновой системы в терапии кардиологических заболеваний в субъектах Дальневосточного федерального округа]

Aim. A comparative analysis of the acquisition pattern of the reninangiotensin- aldosterone system inhibitors for the treatment of cardiovascular diseases in subjects of the Far Eastern Federal District. Material and methods. We used marketing data of pharmacy organizations (n=122) in 2019 in the Khabarovsk Krai (KK), Sakhalin Oblast (SO), and Primorsky Krai (PK). Intra-group analysis, price segmentation, and statistical analysis (Kruskal-Wallis test, Spearman's correlation coefficient, factor analysis) were performed. Results. Angiotensin II receptor blockers (ARBs) are characterized by relatively low levels of sales in KK - 7,67%, in SO - 8,45%, and in PK - 9,75%. Angiotensin-converting enzyme (ACE) inhibitors remain one of the most used cardiovascular medications. In KK, their total share of sales is 28,9%, in SO - 31,12%, in PK - 26,93%. The leaders were losartan and enalapril. There were no significant differences in the distribution of sales between regions. Conclusion. Recently registered medicines (azilsartan, olmesartan, irbesartan, eprosartan), as well as substances with a narrow assortment/without generic drugs (zofenopril, quinapril, fozinopril), are more often characterized by low sales. The maximum sales of most popular ARBs (losartan, valsartan, candesartan) accrue to the price segment of 100-500 rubles. The most popular international nonproprietary names of the ACE inhibitors (captopril, lisinopril, enalapril) are characterized by high sales in price segments <100 rubles. © 2020 Vserossiiskoe Obshchestvo Kardiologov. All rights reserved.